Pharmacokinetics of darbepoetin alfa in pediatric patients with chronic kidney disease

Gary Lerner, Arundhati S Kale, Bradley A. Warady, Kathy Jabs, Timothy E. Bunchman, Anne Heatherington, Kurt Olson, Louise Messer-Mann, Bradley J. Maroni

Research output: Contribution to journalArticle

46 Citations (Scopus)

Abstract

Darbepoetin alfa is a novel erythropoiesis-stimulating protein with a two- to threefold longer half-life than recombinant human erythropoietin (epoetin) in adult patients with chronic kidney disease (CKD). This randomized, open-label, crossover study was conducted to determine the pharmacokinetic profile of darbepoetin alfa in pediatric patients with CKD. Twelve patients 3-16 years of age with CKD were randomized and received a single 0.5 μg/kg dose of darbepoetin alfa administered intravenously (IV) or subcutaneously (SC). After a 14- to 16-day washout period, patients received an identical dose of darbepoetin alfa by the alternate route. After IV administration, the mean clearance of darbepoetin alfa was 2.3 ml/h per kg, with a mean terminal half-life of 22.1 h. After SC administration, absorption was rate limiting, with a mean terminal half-life of 42.8 h and a mean bioavailability of 54%. Comparison of these results with those from a previous study of darbepoetin alfa in adult patients indicated that the disposition of darbepoetin alfa administered IV or SC is similar in adult and pediatric patients, although absorption may be slightly more rapid in pediatric patients after SC dosing. The mean terminal half-life of darbepoetin alfa in this study was approximately two- to fourfold longer than that previously reported for epoetin in pediatric patients.

Original languageEnglish (US)
Pages (from-to)933-937
Number of pages5
JournalPediatric Nephrology
Volume17
Issue number11
DOIs
StatePublished - Dec 1 2002
Externally publishedYes

Fingerprint

Chronic Renal Insufficiency
Pharmacokinetics
Pediatrics
Half-Life
Darbepoetin alfa
Erythropoietin
Cross-Over Studies
Biological Availability

Keywords

  • Anemia
  • Chronic kidney disease
  • Darbepoetin alfa
  • Novel erythropoiesis-stimulating protein
  • Pharmacokinetics

ASJC Scopus subject areas

  • Pediatrics, Perinatology, and Child Health
  • Nephrology

Cite this

Lerner, G., Kale, A. S., Warady, B. A., Jabs, K., Bunchman, T. E., Heatherington, A., ... Maroni, B. J. (2002). Pharmacokinetics of darbepoetin alfa in pediatric patients with chronic kidney disease. Pediatric Nephrology, 17(11), 933-937. https://doi.org/10.1007/s00467-002-0932-0

Pharmacokinetics of darbepoetin alfa in pediatric patients with chronic kidney disease. / Lerner, Gary; Kale, Arundhati S; Warady, Bradley A.; Jabs, Kathy; Bunchman, Timothy E.; Heatherington, Anne; Olson, Kurt; Messer-Mann, Louise; Maroni, Bradley J.

In: Pediatric Nephrology, Vol. 17, No. 11, 01.12.2002, p. 933-937.

Research output: Contribution to journalArticle

Lerner, G, Kale, AS, Warady, BA, Jabs, K, Bunchman, TE, Heatherington, A, Olson, K, Messer-Mann, L & Maroni, BJ 2002, 'Pharmacokinetics of darbepoetin alfa in pediatric patients with chronic kidney disease', Pediatric Nephrology, vol. 17, no. 11, pp. 933-937. https://doi.org/10.1007/s00467-002-0932-0
Lerner, Gary ; Kale, Arundhati S ; Warady, Bradley A. ; Jabs, Kathy ; Bunchman, Timothy E. ; Heatherington, Anne ; Olson, Kurt ; Messer-Mann, Louise ; Maroni, Bradley J. / Pharmacokinetics of darbepoetin alfa in pediatric patients with chronic kidney disease. In: Pediatric Nephrology. 2002 ; Vol. 17, No. 11. pp. 933-937.
@article{e59e086ea73744edb7673ce87df7ede5,
title = "Pharmacokinetics of darbepoetin alfa in pediatric patients with chronic kidney disease",
abstract = "Darbepoetin alfa is a novel erythropoiesis-stimulating protein with a two- to threefold longer half-life than recombinant human erythropoietin (epoetin) in adult patients with chronic kidney disease (CKD). This randomized, open-label, crossover study was conducted to determine the pharmacokinetic profile of darbepoetin alfa in pediatric patients with CKD. Twelve patients 3-16 years of age with CKD were randomized and received a single 0.5 μg/kg dose of darbepoetin alfa administered intravenously (IV) or subcutaneously (SC). After a 14- to 16-day washout period, patients received an identical dose of darbepoetin alfa by the alternate route. After IV administration, the mean clearance of darbepoetin alfa was 2.3 ml/h per kg, with a mean terminal half-life of 22.1 h. After SC administration, absorption was rate limiting, with a mean terminal half-life of 42.8 h and a mean bioavailability of 54{\%}. Comparison of these results with those from a previous study of darbepoetin alfa in adult patients indicated that the disposition of darbepoetin alfa administered IV or SC is similar in adult and pediatric patients, although absorption may be slightly more rapid in pediatric patients after SC dosing. The mean terminal half-life of darbepoetin alfa in this study was approximately two- to fourfold longer than that previously reported for epoetin in pediatric patients.",
keywords = "Anemia, Chronic kidney disease, Darbepoetin alfa, Novel erythropoiesis-stimulating protein, Pharmacokinetics",
author = "Gary Lerner and Kale, {Arundhati S} and Warady, {Bradley A.} and Kathy Jabs and Bunchman, {Timothy E.} and Anne Heatherington and Kurt Olson and Louise Messer-Mann and Maroni, {Bradley J.}",
year = "2002",
month = "12",
day = "1",
doi = "10.1007/s00467-002-0932-0",
language = "English (US)",
volume = "17",
pages = "933--937",
journal = "Pediatric Nephrology",
issn = "0931-041X",
publisher = "Springer Verlag",
number = "11",

}

TY - JOUR

T1 - Pharmacokinetics of darbepoetin alfa in pediatric patients with chronic kidney disease

AU - Lerner, Gary

AU - Kale, Arundhati S

AU - Warady, Bradley A.

AU - Jabs, Kathy

AU - Bunchman, Timothy E.

AU - Heatherington, Anne

AU - Olson, Kurt

AU - Messer-Mann, Louise

AU - Maroni, Bradley J.

PY - 2002/12/1

Y1 - 2002/12/1

N2 - Darbepoetin alfa is a novel erythropoiesis-stimulating protein with a two- to threefold longer half-life than recombinant human erythropoietin (epoetin) in adult patients with chronic kidney disease (CKD). This randomized, open-label, crossover study was conducted to determine the pharmacokinetic profile of darbepoetin alfa in pediatric patients with CKD. Twelve patients 3-16 years of age with CKD were randomized and received a single 0.5 μg/kg dose of darbepoetin alfa administered intravenously (IV) or subcutaneously (SC). After a 14- to 16-day washout period, patients received an identical dose of darbepoetin alfa by the alternate route. After IV administration, the mean clearance of darbepoetin alfa was 2.3 ml/h per kg, with a mean terminal half-life of 22.1 h. After SC administration, absorption was rate limiting, with a mean terminal half-life of 42.8 h and a mean bioavailability of 54%. Comparison of these results with those from a previous study of darbepoetin alfa in adult patients indicated that the disposition of darbepoetin alfa administered IV or SC is similar in adult and pediatric patients, although absorption may be slightly more rapid in pediatric patients after SC dosing. The mean terminal half-life of darbepoetin alfa in this study was approximately two- to fourfold longer than that previously reported for epoetin in pediatric patients.

AB - Darbepoetin alfa is a novel erythropoiesis-stimulating protein with a two- to threefold longer half-life than recombinant human erythropoietin (epoetin) in adult patients with chronic kidney disease (CKD). This randomized, open-label, crossover study was conducted to determine the pharmacokinetic profile of darbepoetin alfa in pediatric patients with CKD. Twelve patients 3-16 years of age with CKD were randomized and received a single 0.5 μg/kg dose of darbepoetin alfa administered intravenously (IV) or subcutaneously (SC). After a 14- to 16-day washout period, patients received an identical dose of darbepoetin alfa by the alternate route. After IV administration, the mean clearance of darbepoetin alfa was 2.3 ml/h per kg, with a mean terminal half-life of 22.1 h. After SC administration, absorption was rate limiting, with a mean terminal half-life of 42.8 h and a mean bioavailability of 54%. Comparison of these results with those from a previous study of darbepoetin alfa in adult patients indicated that the disposition of darbepoetin alfa administered IV or SC is similar in adult and pediatric patients, although absorption may be slightly more rapid in pediatric patients after SC dosing. The mean terminal half-life of darbepoetin alfa in this study was approximately two- to fourfold longer than that previously reported for epoetin in pediatric patients.

KW - Anemia

KW - Chronic kidney disease

KW - Darbepoetin alfa

KW - Novel erythropoiesis-stimulating protein

KW - Pharmacokinetics

UR - http://www.scopus.com/inward/record.url?scp=0036952703&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0036952703&partnerID=8YFLogxK

U2 - 10.1007/s00467-002-0932-0

DO - 10.1007/s00467-002-0932-0

M3 - Article

C2 - 12432437

AN - SCOPUS:0036952703

VL - 17

SP - 933

EP - 937

JO - Pediatric Nephrology

JF - Pediatric Nephrology

SN - 0931-041X

IS - 11

ER -